{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:32:09Z","timestamp":1790620329936,"version":"4.1.0"},"reference-count":33,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T00:00:00Z","timestamp":1569283200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/igo\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>\n                    <ns4:bold>Background:<\/ns4:bold>\n                    While the rise of antimicrobial resistance (AMR) has been recognised as a major public health problem, the value of vaccines to control AMR is poorly defined. This expert survey was launched with the aim of informing the 2018 Vaccine Investment Strategy through which Gavi, the Vaccine Alliance prioritises future vaccine funding. This exercise focused on both vaccines currently supported by Gavi and under consideration for future funding.\n                  <\/ns4:p>\n                  <ns4:p>\n                    <ns4:bold>Methods:<\/ns4:bold>\n                    The relative importance of pre-defined criteria as drivers of overall value of vaccines as a tool\/ intervention to control AMR was assessed by 18 experts: prevention of mortality and morbidity due to resistant pathogens, antibiotic use prevented, societal impact, ethical importance and sense of urgency. For each vaccine, experts attributed scores reflecting the estimated value for each criterion, and overall value relative to AMR was derived from the value assigned to each criterion and their relative importance for each vaccine.\n                  <\/ns4:p>\n                  <ns4:p>\n                    <ns4:bold>Results:<\/ns4:bold>\n                    Mortality, morbidity due to targeted resistant pathogens, and antibiotic use prevented were considered the most important determinants of overall value. Pneumococcal, typhoid and malaria vaccines were assigned highest value relative to antimicrobial resistance. Intermediate value was estimated for specific rotavirus, cholera, respiratory syncytial virus (RSV), influenza, dengue, measles, meningitis and\n                    <ns4:italic>Haemophilus influenza<\/ns4:italic>\n                    type b- (Hib-) containing pentavalent vaccines. Lowest value relative to AMR was estimated for Japanese encephalitis, hepatitis A, yellow fever, rabies and human papilloma virus vaccine.\n                  <\/ns4:p>\n                  <ns4:p>\n                    <ns4:bold>Conclusions:<\/ns4:bold>\n                    In the future, more evidence-based, data-driven, robust methodologies should be developed to guide coordinated, rational decision making on priority actions aimed at strengthening the use of vaccines against AMR.\n                  <\/ns4:p>","DOI":"10.12688\/f1000research.20100.1","type":"journal-article","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T11:30:07Z","timestamp":1569324607000},"page":"1685","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Vaccine impact on antimicrobial resistance to inform Gavi, the Vaccine Alliance\u2019s 2018 Vaccine Investment Strategy: report from an expert survey"],"prefix":"10.12688","volume":"8","author":[{"given":"Maya","family":"Malarski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-4685","authenticated-orcid":false,"given":"Mateusz","family":"Hasso-Agopsowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Soble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Mathewson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3325-9073","authenticated-orcid":false,"given":"Johan","family":"Vekemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2019,9,24]]},"reference":[{"key":"ref-1","article-title":"Tackling Drug-resistant infections globally: Final Report and Recommendations","year":"2016"},{"key":"ref-2","article-title":"Draft political declaration of the high-level meeting of the General Assembly on antimicrobial resistance","year":"2016"},{"key":"ref-3","article-title":"Global Action Plan on Antimicrobial Resistance","year":"2015"},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"318-27","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.","volume":"18","author":"E Tacconelli","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"168-75","DOI":"10.1016\/S0140-6736(15)00474-2","article-title":"Access to effective antimicrobials: A worldwide challenge.","volume":"387","author":"R Laxminarayan","year":"2016","journal-title":"Lancet."},{"key":"ref-6","article-title":"Vaccines and Alternative Approaches: Reducing our Dependence on Antimicrobials","year":"2016"},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"6591-3","DOI":"10.1016\/j.vaccine.2017.09.053","article-title":"Enhancing the role of vaccines in combatting antimicrobial resistance.","volume":"35","author":"C Clift","year":"2017","journal-title":"Vaccine."},{"key":"ref-8","article-title":"The Value of Vaccines in the Avoidance of Antimicrobial Resistance, Meeting Summary","year":"2017"},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"229-31","DOI":"10.1038\/nrd.2018.8","article-title":"Vaccines take a shot at antimicrobial resistance.","volume":"17","author":"K Kingwell","year":"2018","journal-title":"Nat Rev Drug Discov."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"10-9","DOI":"10.1038\/nm.4465","article-title":"The role of vaccines in preventing bacterial antimicrobial resistance.","volume":"24","author":"K Jansen","year":"2018","journal-title":"Nat Med."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"12878-12886","DOI":"10.1073\/pnas.1717159115","article-title":"Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance.","volume":"115","author":"D Kennedy","year":"2018","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"e204-e213","DOI":"10.1016\/S1473-3099(17)30478-4","article-title":"Use of mathematical modelling to assess the impact of vaccines on antibiotic resistance.","volume":"18","author":"K Atkins","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"1455-63","DOI":"10.1056\/NEJMoa051642","article-title":"Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae.","volume":"354","author":"M Kyaw","year":"2006","journal-title":"N Engl J Med."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"1889-99","DOI":"10.1056\/NEJMoa1401914","article-title":"Effects of vaccination on invasive pneumococcal disease in South Africa.","volume":"371","author":"A von Gottberg","year":"2014","journal-title":"N Engl J Med."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"168-75","DOI":"10.1016\/S0140-6736(15)00474-2","article-title":"Access to effective antimicrobials: a worldwide challenge.","volume":"387","author":"R Laxminarayan","year":"2016","journal-title":"Lancet."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"4073-8","DOI":"10.1016\/j.vaccine.2010.03.075","article-title":"Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination.","volume":"28","author":"H Adam","year":"2010","journal-title":"Vaccine."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"750-6","DOI":"10.1086\/605087","article-title":"The effect of universal influenza immunization on antibiotic prescriptions: an ecological study.","volume":"49","author":"J Kwong","year":"2009","journal-title":"Clin Infect Dis."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"12911-12919","DOI":"10.1073\/pnas.1717161115","article-title":"Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR.","volume":"115","author":"J Sevilla","year":"2018","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-19","article-title":"Report from Gavi, the Vaccine Alliance Meeting of the Strategic Advisory Group of Experts on Immunisation (SAGE)","author":"S Berkley","year":"2018"},{"key":"ref-20","article-title":"Vaccine Investment Strategy 2018","author":"Gavi"},{"key":"ref-21","article-title":"Global Burden of Disease Study 2016 (GBD 2016) Population Estimates 1950-2016","year":"2017"},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"e204-13","DOI":"10.1016\/S1473-3099(17)30478-4","article-title":"Use of mathematical modelling to assess the impact of vaccines on antibiotic resistance.","volume":"18","author":"K Atkins","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"ref-23","article-title":"Typhoid fever \u2013 Islamic Republic of Pakistan 2018."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"e26-e30","DOI":"10.1016\/S1473-3099(18)30350-5","article-title":"Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance.","volume":"19","author":"J Andrews","year":"2019","journal-title":"Lancet Infect Dis."},{"key":"ref-25","article-title":"Q&A on the malaria vaccine implementation programme (MVIP)","year":"2019"},{"key":"ref-26","article-title":"Q&A on artemisinin resistance","year":"2018"},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"943-55","DOI":"10.1111\/tmi.12722","article-title":"Aetiologies of non-malaria febrile episodes in children under 5 years in sub-Saharan Africa.","volume":"21","author":"F Kiemde","year":"2016","journal-title":"Trop Med Int Health."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"e1001994","DOI":"10.1371\/journal.pmed.1001994","article-title":"The Future of the RTS,S\/AS01 Malaria Vaccine: An Alternative Development Plan.","volume":"13","author":"R Gosling","year":"2016","journal-title":"PLoS Med."},{"key":"ref-29","article-title":"Vaccines to tackle drug resistant infections","year":"2018"},{"key":"ref-30","article-title":"AHG on Prioritisation of diseases for which vaccines could reduce antimicrobial use in cattle, sheep, and goats","year":"2015"},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"125-37","DOI":"10.1016\/j.jval.2015.12.016","article-title":"Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force.","volume":"19","author":"K Marsh","year":"2016","journal-title":"Value Health."},{"key":"ref-32","article-title":"AMR GAVI VIS Extended data.","author":"M Hasso-Agopsowicz","year":"2019","journal-title":"figshare."},{"key":"ref-33","article-title":"AMR GAVI VIS underlying data.","author":"M Hasso-Agopsowicz","year":"2019","journal-title":"figshare."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/8-1685\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-1685\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-1685\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T06:00:09Z","timestamp":1571637609000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/8-1685\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,24]]},"references-count":33,"URL":"https:\/\/doi.org\/10.12688\/f1000research.20100.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.22068.r54296","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.22068.r54549","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.22068.r54296","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.736685391.793578896","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.22068.r54549","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,24]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/8-1685\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.22068.r54296, William Hausdorff, Faculty of Medicine, Free University of Brussels (ULB), Brussels, Belgium, 01 Oct 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-1685\/v1#referee-response-54296","order":0,"name":"referee-response-54296","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.22068.r54549, David M. Salisbury, Centre on Global Health Security, Chatham House, London, UK, 21 Oct 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-1685\/v1#referee-response-54549","order":1,"name":"referee-response-54549","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution IGO Licence.","order":0,"name":"copyright-info","label":"Copyright"}]}}